Publisher： Adis International
ISSN： 1173-5503
Source： PharmacoEconomics and Outcomes News, Vol.1, Iss.605, 2010-01, pp. : 12-12
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
Alemtuzumab: an effective front-line option for CLL?
Inpharma, Vol. 1, Iss. 1548, 2006-01 ,pp. :
Access to resources
Recommend
Increased risk of infections with alemtuzumab?
Inpharma, Vol. 1, Iss. 1545, 2006-01 ,pp. :
Extraimmunisation in paediatric patients - costly shots?
Inpharma, Vol. 1, Iss. 1229, 2000-01 ,pp. :
SSRI-related adverse events costly?
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 337, 2001-01 ,pp. :
Routine screening for prevention of neonatal kernicterus too costly?
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 467, 2004-01 ,pp. :